Actively Recruiting
Phase I Study to Assess Safety, Tolerability, and Effectiveness of YKST02 in Adults with Relapsed or Refractory Multiple Myeloma
Led by Excyte Biopharma Ltd · Updated on 2026-02-05
70
Participants Needed
12
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating YKST02, a new medicine designed to activate the bodys immune system to fight relapsed or refractory multiple myeloma, a cancer of plasma cells in the blood. This first-in-human study aims to assess the safety, tolerability, how the body processes the medicine, and its initial effectiveness in patients who have already undergone prior treatments. The study is sponsored by Excyte Biopharma Ltd and includes patients aged 18 to 75 years with measurable disease and prior therapies.
CONDITIONS
Brief Title
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Research Team
W
Wenming Chen, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here